CYFRA 21-1在非小细胞肺癌中的预后意义。
Prognostic significance of CYFRA 21-1 in non-small cell lung cancer.
作者信息
Hirashima T, Takada M, Komiya T, Nitta T, Masashi K, Masuda N, Matui K, Kikui M, Yasumitsu T, Kawase I
机构信息
Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.
出版信息
Anticancer Res. 1998 Nov-Dec;18(6B):4713-6.
Between July 1991 and February 1993, CYFRA 21-1 levels of 149 newly diagnosed patients with histologically proven non-small cell lung cancer (NSCLC) at Osaka Prefectural Habikino Hospital were measured with an enzyme immunoassay method developed by Boeringer Mannheim (Enzymun-Test CYFRA 21-1). NSCLC patients with CYFRA 21-1 serum levels over 3.5 ng/ml had a significantly poorer prognosis than did patients with normal CYFRA 21-1 levels (P < 0.001). Univariate analysis revealed that CYFRA 21-1 levels above 3.5 ng/ml, poor PS, advanced stage and serum LDH over 450 U/l strongly correlated with survival period. In multivariate analysis, however, only CYFRA 21-1 was found to be an independent prognostic factor compatible with Stage and PS (P = 0.0040 for CYFRA 21-1, P < 0.001 for PS, P = 0.0052 for Stage).
1991年7月至1993年2月期间，采用勃林格殷格翰公司开发的酶免疫测定法（酶免疫检测CYFRA 21-1），对大阪府羽曳野医院149例经组织学确诊的非小细胞肺癌（NSCLC）新诊断患者的CYFRA 21-1水平进行了检测。CYFRA 21-1血清水平超过3.5 ng/ml的NSCLC患者的预后明显比CYFRA 21-1水平正常的患者差（P < 0.001）。单因素分析显示，CYFRA 21-1水平高于3.5 ng/ml、较差的体能状态（PS）、晚期以及血清乳酸脱氢酶（LDH）超过450 U/l与生存期密切相关。然而，在多因素分析中，仅发现CYFRA 21-1是与分期和PS相符的独立预后因素（CYFRA 21-1的P = 0.0040，PS的P < 0.001，分期的P = 0.0052）。
Zotero 插件